2020
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma
Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro-Oncology 2020, 23: 468-477. PMID: 33085768, PMCID: PMC7992893, DOI: 10.1093/neuonc/noaa240.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBrain NeoplasmsDacarbazineDisease-Free SurvivalEpendymomaHumansLapatinibProspective StudiesSpinal Cord NeoplasmsTemozolomideConceptsProgression-free survivalDose-dense temozolomideMedian progression-free survivalAdult patientsObjective responseSymptom burdenClinical trialsRecurrent ependymomaMD Anderson Symptom Inventory-Brain TumorProspective phase II clinical trialMedian Karnofsky performance statusPhase II clinical trialDemonstrated clinical activityModerate-severe painPatients age 18Phase II studyKarnofsky performance statusProspective clinical trialsSpinal cord tumorsStandard medical treatmentPrimary outcome measureSpinal cord ependymomasDisease-related symptomsExpression of ErbB2Daily lapatinib
2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology 2014, 17: 440-447. PMID: 25121770, PMCID: PMC4483095, DOI: 10.1093/neuonc/nou162.Peer-Reviewed Original ResearchConceptsProgression-free survivalClinical courseEpendymoma patientsMultivariate Cox proportional hazards modelMultivariate Cox proportional hazardsCox proportional hazards modelRare CNS tumorsTime of diagnosisPrognostic clinical factorsCox proportional hazardsProportional hazards modelSubtotal resectionClinical factorsMedian timeCNS tumorsCentral reviewGrade IIIMean ageTumor recurrenceEarly progressionTumor locationGrade IITumor gradeUnivariate analysisSupratentorial location